1. LINE

      Text:AAAPrint
      Sci-tech

      Australia begins production of Oxford-developed COVID-19 vaccine

      1
      2020-11-09 10:48:40Xinhua Editor : Cheng Zizhuo ECNS App Download
      Special: Battle Against Novel Coronavirus

      Australia commenced locally manufacturing a COVID-19 vaccine candidate developed by the University of Oxford from Monday, with roughly 30 million doses planned to be made.

      Despite still undergoing clinical trials, the vaccine, which was co-developed by pharmaceutical company AstraZeneca, is considered one of the more promising vaccines globally.

      Australian biotech firm CSL has agreements with AstraZeneca and the Australian government to begin pre-emptive production of the vaccine, for release during the first half of 2021 should remaining tests prove successful.

      "We are undertaking these manufacturing activities at-risk and in parallel with the clinical trials and approvals processes in recognition of the significant urgency of the COVID-19 pandemic," CSL's Chief Scientific Officer Andrew Nash said.

      It is expected the vaccine will require a two-dose per person regime meaning it could be effectively administered to 15 million people. However, it will not be released for use until the development process is reviewed and approved by Australia's government regulatory authority, the Therapeutic Goods Administration (TGA).

      Production will take place at CSL's bioreactor facility in the State of Victoria, with the manufacturing process beginning by thawing vials containing vaccine cells which had been frozen under liquid nitrogen.

      "After growing in the bioreactors, the vaccine is then filtered and purified leaving just the antigen, or vaccine product. It is then ready for final formulation and filling into dosage vials," the company said in a statement.

      CSL had already manufactured several doses of another COVID-19 vaccine candidate developed by Australia's University of Queensland (UQ), which it is holding in readiness to progress to Phase 2b/3 clinical trials.

      Further trials on the UQ vaccine candidate are due pending the release and review of Phase 1 clinical trial data.

      MorePhoto

      Most popular in 24h

      MoreTop news

      MoreVideo

      LINE
      Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
      Copyright ©1999-2020 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.
      主站蜘蛛池模板: 亚洲视频在线观看| 亚洲精品V欧洲精品V日韩精品| 91亚洲国产成人久久精品网站| 少妇性饥渴无码A区免费| 亚洲精品你懂的在线观看| 色www永久免费| 久久久久亚洲AV无码专区体验| 一级毛片免费观看不卡的| 亚洲伊人久久大香线蕉苏妲己| 1000部拍拍拍18勿入免费凤凰福利| 亚洲黄色免费网站| 成年女人免费视频播放体验区| 亚洲av成人无码网站…| 亚洲AV无码乱码在线观看牲色 | 亚洲视频在线免费| 成人免费乱码大片A毛片| 亚洲Av无码精品色午夜| 亚洲网站免费观看| 久久久久亚洲精品无码网址色欲| 亚洲福利中文字幕在线网址| 国产啪精品视频网站免费尤物| 亚洲色图黄色小说| 国产成人免费片在线视频观看| 久99久无码精品视频免费播放| 久久亚洲中文字幕精品有坂深雪 | 亚洲毛片基地日韩毛片基地| 最近中文字幕无吗免费高清| 国产亚洲视频在线观看网址| 亚洲精品无码久久久影院相关影片 | 在线观看91精品国产不卡免费| h片在线播放免费高清| 亚洲视频在线免费观看| 夫妻免费无码V看片| 成人A毛片免费观看网站| 亚洲女人影院想要爱| 免费大学生国产在线观看p| 中文字幕免费在线看| tom影院亚洲国产一区二区| 亚洲精品国产高清不卡在线| 91在线老王精品免费播放| 免费夜色污私人影院网站电影|